Evofem Swings to $0.9M Profit as PHEXX Sales Fall to $4.6M

Evofem Biosciences swung to net income attributable to common stockholders of $0.9 million, or $0.01 per basic share, in the third quarter of 2026, the company announced on 13 November 2026, as net sales slipped to $4.6 million from $5.0 million a year earlier. Income from operations was $0.7 million, down from $1.0 million in the third quarter of 2025. The San Diego-based pharmaceutical company trades over the counter under the ticker EVFM.

Context — why a profitable quarter still reads as a warning

Evofem's third-quarter profit did not come from growth. Net sales fell year over year, and the company attributed the decline to lower ex-factory PHEXX sales, the ongoing absence of funding for marketing, and a reduction in filled sales territories. Wholesalers kept selling through inventory purchased in December 2025, ahead of a January 2026 price increase, which pushed product into the channel before the quarter began.

The swing to profitability came from the expense side and from non-operating items. Total operating expenses fell to $3.9 million from $4.0 million, and a $1.5 million change in the fair value of financial instruments flipped from a $1.8 million loss a year earlier to a gain. Those two lines, not the top line, carried the quarter.

The prior-year comparison also flatters the 2026 result. The third quarter of 2025 absorbed a $1.9 million gain on a change in accounting estimate tied to a contingent royalty liability, which lifted that period's operating income to $1.0 million even as the company posted a $1.7 million net loss. Stripping that item out, the 2025 quarter was weaker operationally than the headline suggested.

Chief executive Saundra Pelletier framed the result as evidence of cost discipline rather than commercial momentum, saying the quarter reflected the cumulative impact of operating without dedicated growth capital for brand promotion and physician outreach since late 2022. The company said it remains confident in the long-term value of PHEXX and SOLOSEC and believes targeted commercial investment would create opportunities to accelerate growth.

The macro backdrop is not in the report, and the company gave no market-level context for the quarter. What the filing does establish is a balance sheet under strain: cash and cash equivalents stood at zero, with only $0.3 million in restricted cash and cash equivalents as of 30 September 2026.

Data — what the numbers show

The nine-month picture diverges sharply from the quarter. Net sales for the nine months ended 30 September 2026 were $8.2 million against $10.6 million a year earlier, and the company swung to a loss from operations of $6.3 million from income of $27,000 in the comparable 2025 period.

Metric	Q3 2026	Q3 2025
Product sales, net	$4,628k	$4,952k
Total operating expenses, net	$3,888k	$4,001k
Income from operations	$740k	$951k
Net income (loss) attributable to common stockholders	$865k	$(1,680)k
Diluted EPS	$(0.00)	$(0.01)

Nine-month net loss attributable to common stockholders reached $15.8 million, versus $2.5 million a year earlier, driven by a $4.4 million negative change in fair value of financial instruments and a $2.6 million loss on debt extinguishment that did not appear in the prior-year period.

The balance sheet shows total current liabilities of $84.8 million against a total stockholders' deficit of $83.9 million. Trade accounts receivable fell to $3.7 million from $12.5 million at 31 December 2025, a decline consistent with the drop in ex-factory shipments. Total liabilities, convertible and redeemable preferred stock and stockholders' deficit came to $7.3 million, down from $20.3 million at year-end.

Diluted weighted-average shares used in the per-share calculation were 6.81 billion for the quarter, against 124.4 million basic, reflecting the dilutive effect of convertible instruments on a quarter that produced positive net income.

Analysis — what it means for the ticker and the sector

The operational story sits with PHEXX, the hormone-free on-demand contraceptive gel, and SOLOSEC, the single-dose oral antibiotic. Evofem reported shipping its 500,000th box of PHEXX in July 2026, which it described as covering six million acts of sex, and it contracted a second pharmaceutical manufacturer to produce the gel. That second source is a manufacturing-flexibility and cost play, not a demand signal.

The SOLOSEC pipeline runs through an investigator-led, NIH-funded Phase 4 trial comparing single-dose SOLOSEC against a seven-day metronidazole regimen for Trichomonas vaginalis. A fifth study site was added. Investigators hypothesize repeat infection rates will be 1.75 times lower in the SOLOSEC arm and that the single dose will prove more cost-effective despite a higher upfront price. Those are investigator hypotheses, not reported outcomes.

Regulatory work is underway for SOLOSEC in Uganda, the first planned market under an April 2026 distribution agreement with Clovis Davis Pharmaceuticals. Evofem did not disclose financial terms of that agreement.

The counter-argument is straightforward: a $0.9 million quarterly profit built on expense cuts, a fair-value swing and inventory dynamics is not repeatable if sales keep falling. The company's own forward-looking statement flags limited cash resources and its ability to continue as a going concern as material risks. Positioning reflects that tension — the equity is a thin, over-the-counter name where holders are betting on commercial reacceleration, and the absence of growth capital is the constraint the company itself names.

Outlook — what to watch next

Three items carry the next two quarters. First, whether PHEXX ex-factory sales recover once wholesalers finish working through the December 2025 inventory purchased ahead of the January 2026 price increase. Second, progress on the second PHEXX manufacturer and any resulting cost reduction. Third, the Uganda regulatory filing for SOLOSEC and the pace of the Phase 4 trial enrollment.

Evofem gave no revenue guidance and no timeline for raising growth capital. The report also gave no price levels or technical markers for the stock, so there are no defined support or resistance points to cite from the filing. The liquidity line is the one to track: restricted cash and cash equivalents fell to $0.3 million from $0.6 million at 31 December 2025, and the company has disclosed no new financing since.

Frequently Asked Questions

Why did Evofem report a profit when sales fell?

The profit came from below the operating line as much as above it. Operating expenses fell to $3.9 million from $4.0 million, and a $1.5 million favorable change in the fair value of financial instruments reversed a $1.8 million loss in the prior-year quarter. Income from operations of $0.7 million was actually lower than the $1.0 million posted a year earlier.

What is the difference between Evofem's quarterly and nine-month results?

The quarter and the year-to-date period moved in opposite directions. Q3 2026 produced $0.9 million of net income attributable to common stockholders, but the nine months ended 30 September 2026 produced a $15.8 million loss, driven by a $4.4 million fair-value charge and a $2.6 million loss on debt extinguishment. Nine-month net sales fell to $8.2 million from $10.6 million.

Does Evofem have enough cash to fund operations?

The report shows cash and cash equivalents of zero as of 30 September 2026, with $0.3 million in restricted cash and cash equivalents, down from $0.6 million at 31 December 2025. The company's own forward-looking statement cites limited cash resources, its ability to continue as a going concern, and dependence on new capital or business development transactions as material risks. No new financing was disclosed.

Bottom Line

Evofem's $0.9 million quarterly profit came from cost cuts and a fair-value swing, not from the falling PHEXX sales that drive its business.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.